Moderna schedules results as Citi raises target for Moderna stock

Published on 10/14/2026 at 12:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi raised its target from USD 60 to USD 80 on September 30, 2026. Moderna stock costs EUR 192.17 on October 14, 2026 in trading.

Reporting dates and pipeline milestones

Moderna will report third-quarter 2026 results on November 6, 2026.
Second-quarter revenue reached USD 145.00 million, up 2.00 percent year over year.
Moderna stock trades at EUR 192.17 at 11:56 a.m. CEST at Lang & Schwarz on October 14, 2026.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna (ISIN US60770K1079) was trading at EUR 192.17 at Lang & Schwarz on October 14, 2026 at 11:56 a.m. CEST. The company has scheduled its third-quarter 2026 results for November 6, while Citi raised its price target from USD 60 to USD 80 and cut its rating to Sell on September 30, 2026, according to Morningstar.

Three milestones shape the timeline

On September 21, 2026, Moderna announced phase 3 melanoma data for presentation at the European Society for Medical Oncology Congress on October 24, 2026, according to FinanzNachrichten. On September 30, Moderna announced a chief operating officer role, with Juan Andres scheduled to return effective October 5, 2026, the same source reported in its release coverage.

On October 13, 2026, Moderna announced an 8:00 a.m. ET conference call for November 6, 2026, to report third-quarter results and provide a corporate update, as StockTitan reported.

What does the oncology date change?

The October 24 event is the nearer operating milestone. Moderna and Merck are expected to present phase 3 melanoma data from the intismeran autogene program, with the study covering 1,137 patients, according to MarketIV.

That pipeline event contrasts with the latest reported financial base. In the second quarter of 2026, revenue was USD 145.00 million, up 2.00 percent from the prior year, while the net loss was USD 782.00 million, an improvement of USD 43.00 million or 5.00 percent, according to Yahoo Finance. Management reiterated 2026 revenue growth of up to 10.00 percent and reported USD 6.90 billion in cash and investments at quarter-end.

Next reporting and data dates

The next two dated milestones are the October 24, 2026 melanoma data presentation and the November 6, 2026 third-quarter results call. The first is tied to the oncology pipeline; the second will provide the next reported revenue and cash update.

Stock price and market frame

Moderna stock was trading at EUR 192.17 at Lang & Schwarz on October 14, 2026 at 11:56 a.m. CEST. The primary listing is Nasdaq, where the finance snapshot showed USD 216.25 at the October 13, 2026 close, a 52-week range of USD 22.28 to USD 227.46 and market capitalization of USD 85.8 billion.

The further course of trading is shown by the continuously updated real-time quote of Moderna stock.